Full Press Release Details
regeneron to advance two factor xi antibodies into a broad phase 3 program following positive phase 2 proof of concept results.
REGN
regeneron to advance two factor xi antibodies into a broad phase 3 program following positive phase 2 proof of concept results
Key Takeaway: regeneron to advance two factor xi antibodies into a broad phase 3 program following positive phase 2 proof of concept results